Grant List
Represents Grant table in the DB
GET /v1/grants?sort=other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=other_investigators", "prev": null }, "data": [ { "type": "Grant", "id": "14873", "attributes": { "award_id": "1U18HS029937-01", "title": "Supporting Patients Recovering from COVID-19 (SPaRC)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Agency for Healthcare Research and Quality (AHRQ)" ], "program_reference_codes": [], "program_officials": [ { "id": 31564, "first_name": "Latrice", "last_name": "Vinson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-01", "end_date": "2029-06-30", "award_amount": 1000000, "principal_investigator": { "id": 31565, "first_name": "Ann Marie", "last_name": "Parker", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary: Long COVID impacts 10-30% of people after a SARS-CoV-2 infection, with potentially devastating long-term impact on quality of life. Moreover, Long COVID disproportionately affects minority, rural, older, and other at-risk populations. Multidisciplinary Long COVID clinics provide clinical care and offer infrastructure for evaluating promising interventions to improve Long COVID outcomes. The Johns Hopkins Post-Acute COVID-19 Team (JH PACT) is among the country's first and largest Long COVID programs. Via this AHRQ U18 proposal, JH PACT proposes the following Aims: (1) To deliver a comprehensive, multidisciplinary program (Supporting Patients Recovering from COVID, “SPaRC”) to patients with Long COVID, with an expanded focus on underserved populations. The SPaRC program will expand on the existing expertise of the JH PACT multidisciplinary Long COVID outpatient program to increase capacity and decrease wait times, with expanded services to underserved patient populations, including older adult, minority race/ethnicity, socioeconomically disadvantaged, and geographically distant and rural populations via enhanced partnerships with key existing organizations (e.g., Medicine for Greater Good, Center for Clinical Global Health Education). (2) To iteratively evaluate and refine the SPaRC Long COVID program to increase access and improve patient-centered, evidence-based care. The SPaRC program will be evaluated and iteratively refined in quarterly cycles via mixed methods evaluation (via patient data from electronic medical records and semi-structured qualitative interviews of patients/caregivers and staff/clinicians) to inform implementation strategies based on the “Expert Recommendations for Implementing Change” (ERIC) framework within a learning health system. In each review cycle, the implementation team and key SPaRC internal and external stakeholders will evaluate the program and outcomes and select goals for refinement and advancement for the next quarterly review cycle. An external Stakeholder Advisory Council, led by an independent Chair, will provide ongoing feedback via quarterly meetings throughout the project. (3) Partner with regional Long COVID stakeholders, including primary care providers (PCPs), to create and expand access to comprehensive, patient-centered, coordinated Long COVID care across the mid-Atlantic region. We will build a multi-disciplinary Long COVID provider-to-provider e-consult service, customized educational curriculum (delivered via both live and on-demand electronic formats), and continuing education toolkit for PCPs, in conjunction with key stakeholders (e.g., patients, caregivers, community leaders, and PCPs). JH PACT and the SPaRC Team include internationally-recognized experts in Long COVID care, patient outcomes assessment, implementation science, stakeholder/community engagement, and primary care education. JH PACT is ideally positioned to create a Long COVID Center of Excellence, leveraging the outstanding expertise available via Johns Hopkins Medicine, and to optimally engage with the AHRQ Learning Community.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14866", "attributes": { "award_id": "1R01MH136492-01", "title": "SARS-CoV-2 and Social Determinants of Health Impact on Inflammation Associated Depression Risk (SSIDR)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 24495, "first_name": "Douglas L.", "last_name": "Meinecke", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-05", "end_date": "2029-04-30", "award_amount": 833123, "principal_investigator": { "id": 31552, "first_name": "Linda Y.", "last_name": "Kim", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 766, "ror": "https://ror.org/02pammg90", "name": "Cedars-Sinai Medical Center", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "A Global Burden Disease survey commissioned by the World Health Organization (WHO) estimated a 27.6% increase in cases of major depressive disorder (MDD) during the COVID-19 pandemic, particularly among specific vulnerable groups including healthcare workers (HCW), those with pre-existing medical/mental health conditions, as well as ethnic minority communities, many of whom may have their wellbeing challenged from additional stressors compounded by negative social determinants of health (SDOH). Recent findings from the EMBARC study have shown that small lipid molecules called eicosanoids, which act as both activators and suppressors of inflammatory activity as well as modulators of innate and adaptive immunity, are known to have a significant impact on the subacute and chronic sequelae of SARS-CoV-2, in addition to risk for unresolved immune-mediated inflammatory conditions such as CVD. Eicosanoids have also been found to be a contributor of chronic neuroinflammatory conditions such as depression in other studies. Advanced mass spectrometry methods now allow for the rapid and accurate quantification of hundreds of upstream eicosanoid mediators representing multiple enzymatic origins. Hence, this proposal aims to provide a more detailed understanding of how upstream eicosanoid pathways can be variably active, imbalanced, and perturbed in relation to an individual’s propensity for developing depression. We will leverage the expertise of an interprofessional team, including current members of the EMBARC research study team, to test the hypothesis that: 1) SARS-CoV-2 infection and reinfections moderate development of chronic immune-mediated neuroinflammatory condition such as depression as evidenced by changes in eicosanoid profiles; and 2) health impacts of SDOH compounds depression risk following SARS-CoV-2 infection and reinfection by moderating the neuroimmune-inflammatory response. We propose a systematic approach to comprehensively investigating the components of upstream inflammatory activity in relation to outcomes across the spectrum of depression risk through the collection of longitudinal (survey, clinical, biomarker) data from a large and diverse population of people already enrolled in the EMBARC research study and will use a variety of methods (e.g., eicosanoid profiling, use of public available health equity data set) to assess SARS-CoV-2 infection and the SDOH impact on neuroinflammation that is associated with depression. This work will pave the way for follow-up studies investigating the efficacy of anti- inflammatory therapies, including both existing and novel agents, for modulating variation in distinct eicosanoids and, in turn, mental health outcomes such as depression.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14969", "attributes": { "award_id": "5R21AI178831-02", "title": "Anti-inflammatory activity of hydrogels designed to capture extracellular inflammasomes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6717, "first_name": "Conrad M.", "last_name": "Mallia", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2025-06-30", "award_amount": 183186, "principal_investigator": { "id": 27585, "first_name": "Eva", "last_name": "de Alba Bastarrechea", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2040, "ror": "https://ror.org/00d9ah105", "name": "University of California, Merced", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Multiprotein complexes known as inflammasomes form in innate immune cells to trigger inflammation upon detection of pathogens or tissue damage. Abnormal inflammasome activation leads to chronic inflammation, which is the culprit of numerous life-threatening diseases such as cancer, diabetes, cardiovascular disorders, and the cytokine storm in SARS-CoV-2 infection. Inflammasome assembly is controlled by protein-protein interactions as it requires the self-association and oligomerization of multiple copies of three proteins: sensors to detect danger signals, a protease to activate inflammatory factors, and the adaptor protein ASC to connect sensor and protease. Inflammasome formation leads to plasma membrane rupture and concomitant cell death, thus resulting in the release of proinflammatory cytokines and inflammasome particles to the extracellular environment. These extracellular inflammasomes are internalized by nearby cells to perpetuate and amplify the inflammatory response. Removing or sequestering extracellular inflammasomes will likely inhibit or reduce inflammation. Therefore, extracellular inflammasomes are potential therapeutic targets. Our laboratory’s extensive experience on the function and structure of the adaptor ASC, and its interactions with other inflammasome proteins, has led us to create hydrogels designed to form specific protein-protein interactions with inflammasomes; thus, they have the potential to broadly inhibit inflammation by effectively capturing and removing extracellular inflammasomes. This project focuses on identifying the hydrogelation factors leading to optimum biding of inflammasome particles in cell-free systems (Aim 1); and determining the anti-inflammatory efficiency of the hydrogels in the presence of activated innate immune cells (Aim 2). Our experimental plan will combine cell biology and biochemical approaches, including live/dead cell imaging, flow cytometry, immunoblotting, enzyme-linked immunosorbent assays and fluorescence spectroscopy. Overall, we expect to develop a hydrogel technology of broad applicability to reduce inflammation in the absence of drug loading by targeting the inflammasome, which is implicated in many inflammatory diseases.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14946", "attributes": { "award_id": "5R01HL169760-02", "title": "Bispecific immunotherapeutic delivery system for lung diseases", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22589, "first_name": "CHRISTIAN RENE", "last_name": "Gomez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-01", "end_date": "2027-05-31", "award_amount": 905828, "principal_investigator": { "id": 28090, "first_name": "Jan Eugeniusz", "last_name": "Schnitzer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2076, "ror": "", "name": "PROTEOGENOMICS RESEARCH INSTIT/SYS/ MED", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Modern medicine has created precision drugs blocking a single therapeutic target like TGF-β with high affinity and specificity. Yet treating lung diseases remains challenging in part because lung microvascular endothelium represents a key restrictive barrier to effective drug delivery. Current systemic therapeutics rely solely on convection and diffusion to extravasate passively into the tissue interstitium where disease targets and cells can readily be reached and directly treated. The goal of this research proposal is to design, develop and test a novel drug delivery system for immunotherapeutics that overcomes this key barrier by targeting caveolae to facilitate active and specific transcytosis into lungs after intravenous injection. The ideal is to deliver the entire therapeutic dose inside the lung tissue with all other tissues minimally exposed. We attempt to approach this ideal by achieving robust transendothelial pumping precisely into lung tissue to comprehensively block the therapeutic target TGF-β, which regulates inflammation and remodeling in diseased tissues. Because TGF-β also exerts various homeostatic effects in many organs, caution is necessary when systemic targeting of its function is attempted. Precision lung targeting proposed here will maximize efficacy and therapeutic indices by minimizing dosages, eliminating toxicities, and reducing cost of treatment. To that end, we have genetically engineered the first “dual precision” immunotherapeutics, namely bispecific antibodies in quad format with one arm pair mediating precise binding/delivery to and penetration of lung tissue via caveolae pumping and the other pair constituting the precision therapeutic modality that blocks TGF-β effector function. Active transendothelial delivery improved precision lung targeting by 100-fold over standard passive transport. Delivering most of the injected dose into lungs within 1 hour enhanced therapeutic potency by >1000-fold in a rat pneumonitis model. Now our goal is to expand this promising preliminary work and further improve and rigorously test this drug delivery system to treat key lung diseases at distinct stages ranging from early acute inflammation to chronic and progressive fibrosis. We will optimize lung targeting of our dual precision immunotherapeutics and study their specific lung delivery, penetration, accumulation, localization, and therapeutic impact in rats using multiple imaging techniques (SPECT-CT, IVM, EM, and IHC). Therapeutic effects will be assessed in a rat bleomycin model that reproduces pathological hallmarks of many fatal human diseases including ALI, ARDS, COVID, pneumonias, and fibrosis. Our specific aims are: 1) to engineer and evaluate distinct caveolae-targeted antibody constructs for precision active delivery into normal lung tissue, 2) to quantify targeting and optimize delivery of bispecific immunotherapeutics in lung disease, 3) to test efficacy of bispecific immunotherapeutics to ameliorate lung disease and block TGF-β pathways. This work sets a foundation for caveolae-targeted therapies and could begin a paradigm shift from passive to active drug delivery for many diseases.", "keywords": [ "Acute", "Acute Respiratory Distress Syndrome", "Address", "Affect", "Affinity", "Animals", "Antibodies", "Antiinflammatory Effect", "Automobile Driving", "Binding", "Biodistribution", "Biological Markers", "Biological Products", "Bispecific Antibodies", "Bleomycin", "Blood Vessels", "COVID-19", "Cause of Death", "Caveolae", "Cells", "Cessation of life", "Chimeric Proteins", "Chronic", "Clinical", "Convection", "Cytokine Signaling", "Data", "Diffusion", "Disease", "Dose", "Drug Delivery Systems", "Drug Targeting", "Endothelial Cells", "Endothelium", "Engineering", "Exhibits", "Extravasation", "Fibrosis", "Foundations", "Genetic Engineering", "Goals", "Histopathology", "Hour", "Image", "Imaging Techniques", "Immunotherapeutic agent", "In Vitro", "Inflammation", "Inflammatory", "Intravenous", "Lung", "Lung Diseases", "Magic", "Mediating", "Modality", "Modeling", "Modern Medicine", "Organ", "Pathologic", "Pathology", "Pathway interactions", "Penetration", "Pharmaceutical Preparations", "Phosphorylation", "Physiology", "Pneumonia", "Pre-Clinical Model", "Precision therapeutics", "Preclinical Testing", "Property", "Pulmonary Inflammation", "Pulmonary Pathology", "Pump", "Rattus", "Research Proposals", "Rodent", "Signal Transduction", "Site", "Specificity", "Structure of parenchyma of lung", "System", "Testing", "Therapeutic", "Therapeutic Effect", "Therapeutic Index", "Time", "Tissues", "Toxic effect", "Transforming Growth Factor beta", "Treatment Cost", "Treatment Efficacy", "Vascular Endothelial Cell", "Vascular Endothelium", "Work", "Workplace", "arm", "comparative", "design", "dosage", "drug testing", "efficacy testing", "expectation", "human disease", "improved", "intravenous injection", "novel", "novel therapeutics", "passive transport", "pneumonitis and fibrosis", "precision drugs", "prevent", "prophylactic", "protein expression", "prototype", "research clinical testing", "response", "single photon emission computed tomography", "targeted treatment", "therapeutic target", "therapy outcome", "transcytosis", "uptake" ], "approved": true } }, { "type": "Grant", "id": "14886", "attributes": { "award_id": "1R01NS136806-01", "title": "Cerebral Energy Metabolism in ME/CFS with and without PASC", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 10999, "first_name": "Vicky R", "last_name": "Whittemore", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-01", "end_date": "2029-06-30", "award_amount": 670721, "principal_investigator": { "id": 23743, "first_name": "Xiang", "last_name": "Xu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Many patients who have recovered from SARS-CoV-2, the virus that causes COVID-19, continue to experience a constellation of symptoms long after the initial illness. Known as “long-COVID”, or Post- Acute Sequelae of SARS-Cov-2 infection (PASC), the most frequently reported symptoms are fatigue, post exertional malaise and cognitive dysfunction, which are also the primary symptoms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Many of the PASC patients fulfill diagnostic criteria for ME/CFS, but differ from non-PASC ME/CFS patients in that they share a common infectious trigger and have a shorter duration of illness, which reduces heterogeneity. Understanding whether PASC ME/CFS shares overlapping mechanisms with non-PASC ME/CFS is critical, as this could provide insights into the mechanisms and inform treatment strategies of ME/CFS in general. To address this question, we propose a comparison study of PASC ME/CFS patients with sudden onset illness to non-PASC ME/CFS patients who reported a sudden flu-like illness onset. Limited studies have shown reductions in cerebral blood flow and increased cerebroventricular lactate in ME/CFS patients suggesting alterations in perfusion and metabolic properties. Our recent preliminary results show that the oxygen extraction fraction was elevated in PASC ME/CFS patients, which may be attributed to reduced cerebral blood flow and mitochondrial dysfunction. In this project, we aim to conduct non- invasive brain magnetic resonance imaging (MRI) to compare the similarities and differences in cerebral oxygen and glucose metabolism between the two patient groups as well as healthy controls. We will measure and compare the oxygen extraction fraction, cerebral blood flow, and cerebral metabolic rate of oxygen and glucose uptake and metabolic rate in the patient groups and healthy controls. The MRI derived parameters will then be correlated to the disease symptom burden. Additional, since many PASC patients recover over one year, we aim to perform a follow-up study on the PASC and non-PASC ME/CFS groups. Completion of this timely and important study will provide comparison of PASC and non-PASC ME/CSF in terms of changes in glucose and oxygen metabolic properties, as well as how these imaging parameters are related to the disease burden. Through analysis of the longitudinal data, we will be able to determine whether the changes in metabolic properties are associated with changes of patient reported outcome measures. The knowledge learned will deepen our understanding of the ME/CFS/PASC (long-COVID) disease mechanisms, aid in ME/CFS diagnosis, inform treatment decisions, and inspire new treatment targets.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14858", "attributes": { "award_id": "1R13ES036854-01", "title": "2024 International Meeting of the Pacific Basin Consortium for Environment and Health", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Environmental Health Sciences (NIEHS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22577, "first_name": "Brittany", "last_name": "Trottier", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-09", "end_date": "2025-06-30", "award_amount": 48000, "principal_investigator": { "id": 27582, "first_name": "Stephania A", "last_name": "Cormier", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1505, "ror": "", "name": "LOUISIANA STATE UNIV A&M COL BATON ROUGE", "address": "", "city": "", "state": "LA", "zip": "", "country": "United States", "approved": true }, "abstract": "The Pacific Basin Consortium for Environment and Health (PBC) will partner with Louisiana State University Superfund Research Program (LSU SRP) investigators to develop a series of meetings on topical themes. An alternating schedule of one-day focus meetings on hot topics and full International Conferences has been planned from 2021 to 2026. This application (bolded below) is limited to the 2024 international meeting, but the full plan is outlined for context. • 2021 Focus meeting, Brisbane, Australia, Environmental impacts on infectious disease. [R13 2021] • 2022 Conference, Jeju Island South Korea, Environmental exposures in a changing climate. [R13 2022] • 2023 Focus meeting, Louisiana State University, USA, Pandemic planning – lessons from COVID-19. • 2024 Conference, Ho Chi Minh City, Vietnam, Bidirectional Interactions between Climate and Health • 2025 Focus meeting, CRI Bangkok, Thailand, Theme TBA. • 2026 Conference, NIAID Phnom Penh, Cambodia, Theme TBA. International meetings will be held within universities (or similar) over three and a half-days, facilitating virtual attendance and participation, and include training workshops, plenary sessions, symposia, poster presentation sessions, and a dedicated unopposed session for student oral presentations. The Focus meetings and Conference themes align with the NIEHS the SRP Strategic Plan 2020-2025 and NIEHS Strategic Goals 2018-2023, advancing environmental health sciences, promoting the translation of scientific knowledge to action, and enhancing environmental health sciences through stewardship and support. The PBC has a long history of working with regional Universities and Professional Societies to maximize the participation of local trainees (students and postdoctoral fellows) and junior faculty in line with SRP goals. All PBC Conferences have similar objectives: promoting human and environmental health through education and practice in toxicology, engineering, and sanitation, and focusing on priority environmental health issues in the host country. Each conference has been attended by 250-300 participants with 60% or more coming from the Asia- Pacific region. We request $50,000 from NIEHS to (i) facilitate conference organization, (ii) incentivize the participation of trainees, early career researchers, and young professionals, with a particular focus on female and underrepresented minority participation, through travel grants and registration waivers, and (iii) facilitate the attendance of local trainees through accommodation and registration support. The meeting program costs are estimated at $100,000. Additional support will come from the PBC, LSU, Pennington Biomedical Research Center, and the non-profit organization for Advancing Research for Children's Environmental Health (ARCeH).", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14961", "attributes": { "award_id": "5R01NS129836-02", "title": "Mechanisms and Functions of Cortical Activity to Restore Behavior", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 22923, "first_name": "Janet", "last_name": "He", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-07-01", "end_date": "2028-06-30", "award_amount": 487477, "principal_investigator": { "id": 27578, "first_name": "Diany Paola", "last_name": "Calderon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 825, "ror": "", "name": "WEILL MEDICAL COLL OF CORNELL UNIV", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Monitoring the transition to wakefulness is critical during restoration to consciousness after brain injury, anesthesia, and in those COVID-19 survivors that have altered consciousness. However, we have an imprecise understanding of neural dynamics linked to behavioral changes as subjects awaken. Our previous work discovered that stimulating the anterior nucleus gigantocellularis (aNGC) promotes arousal from a coma-like state. We proposed recruiting multiple arousal pathways through aNGC as an avenue to triggering widespread activation resulting in wakefulness. Notably, aNGC activation increased frontal-motor cortical activity and restored full mobility through modulation of an aNGC-to-frontal-motor-cortex pathway despite high anesthetic concentration exposure. We also showed that animals emerging from diverse coma-like states share a common dynamic process of cortical and motor arousal that can be consistently sequenced from deep to high arousal levels. We identified five cortical periods that tracked restored motor behavior in a hypoglycemic coma and a range of anesthetics, whether inhaled or injected, alongside conventional righting reflex assays. Based on these findings, we postulate that restoring waking is a common progressive process in which cortical patterns contain metrics of consciousness that distinguish reflexive from purposeful movements. We hypothesize that cortical measurements that link neural responsiveness to defined behaviors are an applicable method that can extend the analysis of the recovery of consciousness beyond monitoring reflexive movements. Our proposal deepens our understanding of the contribution of cortical neural subtypes, the neuronal pathways underlying aNGC-induced changes in frontal-motor cortical activity, and the temporal dynamics that distinguish reflexive from the initiation of voluntary behaviors in our rodent-low arousal models. In addition, we will establish the cortical patterns that unpack these behavioral transitions. Since pathological states of unconsciousness are vastly heterogeneous, having a clear understanding of ordinary recovery serves to better appreciate the variability imposed by the injury to cortical activity and behavior. Thus, we will identify how damaged neural circuits affect established cortical activity pathways and dynamics that underlie behavior recovery. The proposed studies are thus significant because they will establish the mechanistic correspondence, examining activation of neural pathways and their dynamics linked to habitual and intentional behaviors that reveal novel, medically relevant biomarkers that promote a robust inference of arousal states during emergence from anesthesia and after brain injury.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14953", "attributes": { "award_id": "5R01HS029477-02", "title": "Cognitive Behavioral Faith-based Depression Intervention For African American Adults (CB-FAITH): An Effectiveness And Implementation Trial", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Agency for Healthcare Research and Quality (AHRQ)" ], "program_reference_codes": [], "program_officials": [ { "id": 24451, "first_name": "Brenda", "last_name": "Harding", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-01", "end_date": "2028-05-31", "award_amount": 385818, "principal_investigator": { "id": 28114, "first_name": "Earlise C", "last_name": "Ward", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "Recent research shows the prevalence of depression symptoms in the US was more than 3-fold higher during COVID-19 compared with before the COVID-19 pandemic. Prevalence of depression among Blacks pre- COVID was 8.4% and during-COVID pandemic 24.2%. Although the prevalence of depression is comparable among Blacks and Whites, the difference is dramatically reversed for severe depression. African Americans/Blacks have higher symptom levels for chronicity and disability, 56.5% vs. 38.6% for Whites. These disparities are even more stark for African Americans in the Madison, Wisconsin the proposed research site. Blacks in Wisconsin are 50% more likely than Whites to report having frequent mental distress. Despite the burden of living with depression, African Americans do not seek mental health services at comparable rates to other demographic groups. National mental health service use data show Whites use at 23.0% and African Americans at 13.6% in the past 12 months. Culturally adapted treatments designed for African American adults have the potential to address and potentially stop these health disparities; research shows culturally adapted treatments to be four times more effective than standardized care. Despite growing literature indicating African Americans are more likely to use religious coping when experiencing mental illness, empirically validated culturally adapted faith-based depression interventions do not exist for this group. To address this gap, the PI forged transformative partnerships with the African American Council of Churches to develop a faith-based intervention: Cognitive Behavioral Faith Fellowship to Improve Thy Health (CB-FAITH). CB FAITH is spiritually- based whereby spiritual/religious themes, stories, and scripture are integrated in the core cognitive behavioral content. The 13-treatment modules focus on increasing knowledge of depression and healthy coping behaviors. It is designed to be co-delivered by African American licensed mental health clinicians and African American pastors at churches. We propose conducting a hybrid type 1 effectiveness-implementation trial employing a stepped wedge cluster randomized design with church groups as the unit of randomization, providing simultaneous testing of the intervention and assessment of barriers and facilitators to implementation of the intervention. The sample will be comprised of 10 groups, each with 12 individuals (N=120) who identify as African American men and women (age 25 and older) with clinical depression. Clinical outcomes will be measured at baseline, weeks 6 and 12 during the intervention, and post-intervention at 3 and 6 months. For the implementation arm of the study, we will use the RE-AIM conceptual framework to examine implementation. Use of surveys and semi-structured interviews focusing on RE-AIM concepts at individual and organizational level will be conducted during and at the end of the intervention implementation. Results of this trial has the potential to advance the AHRQ’s goal of achieving equity in the delivery of healthcare services. .", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14931", "attributes": { "award_id": "5R01MH135477-02", "title": "Investigation of Digital Media Use, Anxiety, and Biobehavioral Emotion Regulation in Adolescents", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 28277, "first_name": "Laura A.", "last_name": "Thomas", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-08", "end_date": "2028-06-30", "award_amount": 682529, "principal_investigator": { "id": 28278, "first_name": "Sarah C", "last_name": "Myruski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 833, "ror": "", "name": "PENNSYLVANIA STATE UNIVERSITY, THE", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Anxiety symptom onset peaks in adolescence, with an estimated one in three teens experiencing clinically-significant symptoms by age 18 years. Adolescent anxiety confers risk for adulthood anxiety disorders, as well as poor outcomes in multiple domains including overall health and interpersonal functioning. Over the past several decades, the social world of teens has been transformed by pervasive use of digital media (e.g., social media, messaging apps) ingrained in daily life. Both adolescent anxiety and digital media use have continued to become increasingly prevalent throughout the COVID-19 pandemic, highlighting the urgent need for rigorous investigations of longitudinal and mechanistic links between digital technology use and mental health. Guided by three major gaps in the literature, the proposed study will (1) capture how youth engage in digital media use in ways that facilitate or disrupt social connectedness, (2) examine when youth use digital media in the context of momentary affect and anxiety in daily life, and (3) address why digital media use may be beneficial or detrimental for some by examining mechanistic links among biobehavioral cognitive and affective functioning, digital media use, and anxiety. In particular, adolescence is a critical period of neurodevelopment in frontal-subcortical circuitry underlying emotion regulation, the implicit and explicit processes by which we manage emotions, and a major predictor of anxiety disorders. This study will leverage an innovative, multi-method (i.e., questionnaires, interviews, reaction time, eye-tracking, EEG) biobehavioral assessment of emotion regulation coupled with ecological momentary assessment (EMA) of within-person daily patterns of digital media use, emotional experiences, anxiety symptoms, and emotion regulation measured longitudinally in teens. We will index youths' emotion regulation strengths and vulnerabilities by (1) contextualizing emotion regulation within adolescents' daily life, (2) targeting both explicit and implicit regulatory processes, and (3) capturing biobehavioral aspects of ER that reflect rapid attentional processes, cognitive control, and flexibility. This work is in line with the Research Domain Criteria initiative to investigate developmental change within ecologically-valid environments by integrating measurement across multiple domains [(negative valence (potential threat), cognitive systems (attention, control), social processes (communication, connectedness), arousal (affective states)] and across units of analysis (physiology, behaviors, paradigms, self-reports). This research aligns with the NIH-wide strategic plan emphasizing the need to illuminate the role of technology and media use in development and will contribute to NIMH's Objective 2 by furthering the interrogation of biobehavioral indicators related to anxiety symptom trajectories in youth. Findings from this research have the potential to elucidate the impact of digital media use on vulnerable individuals and inform recommendations for healthy technology use.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14894", "attributes": { "award_id": "1R01AI178605-01A1", "title": "A NOVEL STRATEGY TO INHIBIT SARS-COV-2 INFECTION AND COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6115, "first_name": "DIPANWITA", "last_name": "Basu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-06-13", "end_date": "2029-04-30", "award_amount": 697983, "principal_investigator": { "id": 31583, "first_name": "PHILIPPE ANDRE", "last_name": "GALLAY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 745, "ror": "", "name": "SCRIPPS RESEARCH INSTITUTE, THE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "While the development of effective vaccines against CoV-2 is cause for optimism, vaccine hesitancy in developed countries and shortages in low-income countries are jeopardizing efforts to curb the pandemic. Out of the 6.4 billion people living in low-income countries, only 2% have access to vaccines. Consequently, the conditions are ripe for continued spike mutation and evolution to increasingly transmissible strains causing more severe illness. Some of these emerging strains may even challenge the protection of vaccines. In this application, we propose a novel therapeutic approach for the eradication of CoV-2. We developed a new strategy, which consists of hijacking the viral replication machinery to trigger the death of CoV-2-infected cells, while preserving uninfected cells. We propose to administer intranasally human ACE2 transgenic mice and Syrian hamsters a “tailored” RNA encoding the diphtheria toxin fragment A (DTA) called {CoV-2 Hijack DTA} that is only recognized and transcribed by the CoV-2 polymerase (Pol/RdRp) present in infected cells, triggering DTA expression and rapid death of infected cells. Since DTA cannot cross the cellular membrane, it cannot kill uninfected cells. Because RNA can be easily broken down in the body, it needs to be transported within a protective carrier. Noninvasive aerosol inhalation is a well-established method of drug delivery to the respiratory tract and represents an ideal route for nucleic-acid-based therapeutics as demonstrated in various clinical trials. We propose to design degradable polymer-lipid nanoparticles (LNPs) that can deliver RNAs by nebulization (inhalation) to the respiratory tract. We propose to synthesize hyperbranched poly-beta amino esters (hPBAEs) to enable nanoformulation by nebulizer of stable and concentrated polyplexes suitable for inhalation. This strategy should achieve uniform distribution of RNAs throughout lungs resulting in high levels of proteins of interest 24h post-inhalation of hPBAE polyplexes without local or systemic toxicity due to rapid degradation of hPBAE vectors. The safety and antiviral efficacy of nebulized {CoV-2 Hijack DTA} RNA LNPs stably protected by degradable hPBAEs will be analyzed. Our in vivo imaging IVIS Lumina S5 system permits a daily bioluminescence (NanoLuc-CoV-2) or fluorescence (mNeonGreen CoV-2) quantification of the {CoV-2 Hijack DTA} RNA LNPs-mediated killing of infected lungs in live animals. We will investigate the MoA causing the killing of CoV-2-infected cells by {CoV-2 Hijack DTA}. We will use complementary approaches to determine whether {CoV-2 Hijack DTA} triggers apoptosis, membrane permeability and/or chromosomal degradation leading to cell killing. By scRNA-Seq, we will analyze i) the specific killing of infected cells at high resolution on large numbers of cells exposed to {CoV-2 Hijack DTA}; ii) the global map of apoptotic DNA breakpoints such as DNA fragmentation; and iii) the phenotype of immunological target cells. We will examine whether {CoV-2 Hijack DTA} RNA LNPs counteract the deleterious inflammatory response, which occurs during CoV-2 infection including histopathological lesion development, interstitial pneumonia and cytokine cascade.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1, "pages": 1392, "count": 13920 } } }